drugset / Trial / NCT00972855

Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fed Conditions

NCT00972855

Phase 1 Completed 60 enrolled Teva Pharmaceuticals USA
RandomizedParallel-groupOpen-label

Summary

The objective of this study is to compare the rate and extent of absorption of bicalutamide 50 mg tablets (test) versus Casodex® (reference) administered as 1 x 50 mg tablet under fed conditions.

Timeline

Start
2003-09
Primary completion
2003-09
Completion
2003-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bicalutamide Other / unclassified 50 mg

Indications

No indication recorded.